This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: University of Massachusetts. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010
Title: Bradford M. Stadler: Innovator in RNA Interference Technologies
Introduction
Bradford M. Stadler is a notable inventor based in Marlborough, MA (US). He has made significant contributions to the field of RNA interference (RNAi) through his innovative research and patent developments. His work focuses on the use of structured viral non-coding RNAs (svRNAs) in identifying druggable targets and developing antiviral agents.
Latest Patents
Stadler holds a patent titled "Virally-encoded RNAs as substrates, inhibitors and delivery vehicles for RNAi." This invention provides methods for identifying druggable targets in assays that feature compositions, cells, and organisms with svRNAs and an RNAi pathway. The patent also outlines methods for identifying antiviral agents and creating vaccines. Furthermore, it includes methods for inhibiting RNAi involving svRNAs or their inhibitory derivatives. The invention offers compositions for delivering siRNA and miRNA molecules derived from svRNA loci, along with therapeutic methods for their use.
Career Highlights
Bradford M. Stadler is affiliated with the University of Massachusetts, where he continues to advance research in RNA technologies. His work has garnered attention for its potential applications in drug development and therapeutic interventions.
Collaborations
Stadler collaborates with Timothy F. Kowalik, enhancing the research efforts in their field. Their partnership exemplifies the importance of teamwork in scientific innovation.
Conclusion
Bradford M. Stadler's contributions to RNA interference technologies highlight his role as a leading inventor in the field. His innovative patent and ongoing research at the University of Massachusetts pave the way for future advancements in antiviral therapies and drug development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
